NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis $2.99 +0.04 (+1.36%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.90▼$3.1550-Day Range$2.77▼$6.0952-Week Range$2.62▼$23.25Volume19,965 shsAverage Volume80,716 shsMarket Capitalization$5.44 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioCardia alerts: Email Address BioCardia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside33.8% Upside$4.00 Price TargetShort InterestHealthy2.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingAcquiring Shares$8,278 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($6.30) to ($7.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.76 out of 5 stars 3.3 Analyst's Opinion Consensus RatingBioCardia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioCardia has only been the subject of 1 research reports in the past 90 days.Read more about BioCardia's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.28% of the float of BioCardia has been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCardia has recently decreased by 38.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCDA. Previous Next 2.6 News and Social Media Coverage News SentimentBioCardia has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioCardia this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,278.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.00% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.57% of the stock of BioCardia is held by institutions.Read more about BioCardia's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BioCardia are expected to decrease in the coming year, from ($6.30) to ($7.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCardia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About BioCardia Stock (NASDAQ:BCDA)BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.Read More BCDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCDA Stock News HeadlinesJuly 25 at 8:11 AM | stockhouse.comPatient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart FailureJuly 17, 2024 | globenewswire.comBioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal ApplicationJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 7, 2024 | globenewswire.comBioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery ApproachMay 22, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces Reverse Stock SplitMay 21, 2024 | globenewswire.comBioCardia Announces Reverse Stock SplitMay 18, 2024 | finance.yahoo.comBioCardia, Inc. (BCDA)May 15, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 15, 2024 | finance.yahoo.comBioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...May 14, 2024 | investorplace.comBCDA Stock Earnings: BioCardia Reported Results for Q1 2024May 14, 2024 | globenewswire.comBioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsMay 14, 2024 | finance.yahoo.comMost Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is ReasonableMay 9, 2024 | globenewswire.comBioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024May 1, 2024 | finance.yahoo.comBioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesMay 1, 2024 | globenewswire.comBioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesApril 25, 2024 | globenewswire.comBioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortApril 1, 2024 | finance.yahoo.comBioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call TranscriptSee More Headlines Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCDA CUSIPN/A CIK925741 Webwww.biocardia.com Phone(650) 226-0120Fax310-861-5299Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,913.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($7.0465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,570,000.00 Net Margins-2,208.76% Pretax Margin-2,208.76% Return on Equity-3,638.68% Return on Assets-261.66% Debt Debt-to-Equity RatioN/A Current Ratio0.31 Quick Ratio0.31 Sales & Book Value Annual Sales$480,000.00 Price / Sales11.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-2.68Miscellaneous Outstanding Shares1,820,000Free Float1,457,000Market Cap$5.42 million OptionableOptionable Beta1.37 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Peter A. Altman Ph.D. (Age 57)CEO, President & Director Comp: $515.51kMr. David McClung (Age 61)Chief Financial Officer Comp: $370.86kMr. Edward M. Gillis (Age 62)Senior Vice President of Devices Comp: $263.1kKey CompetitorsJanOneNASDAQ:JANCara TherapeuticsNASDAQ:CARAiBioNYSE:IBIOJanoneNASDAQ:ALTSVBI VaccinesNASDAQ:VBIVView All CompetitorsInsidersPeter AltmanBought 300 shares on 7/1/2024Total: $915.00 ($3.05/share)Peter AltmanBought 200 shares on 6/28/2024Total: $598.00 ($2.99/share)Peter AltmanBought 500 shares on 6/21/2024Total: $1,645.00 ($3.29/share)Peter AltmanBought 500 shares on 6/14/2024Total: $1,760.00 ($3.52/share)Peter AltmanBought 1,000 shares on 6/10/2024Total: $3,360.00 ($3.36/share)View All Insider Transactions BCDA Stock Analysis - Frequently Asked Questions How have BCDA shares performed this year? BioCardia's stock was trading at $9.9630 at the beginning of the year. Since then, BCDA stock has decreased by 70.0% and is now trading at $2.99. View the best growth stocks for 2024 here. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($1.35) earnings per share (EPS) for the quarter. The firm earned $0.06 million during the quarter. BioCardia had a negative trailing twelve-month return on equity of 3,638.68% and a negative net margin of 2,208.76%. When did BioCardia's stock split? BioCardia's stock reverse split before market open on Thursday, May 30th 2024. The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK) and Aurcana Silver (AUNFF). This page (NASDAQ:BCDA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
